Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 13/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642705 | 0.93 | RIPK2 (0.51) | PTGER4RIPK2KDM4EHPGDNPSR1 | |
| SCHEMBL14616827 | 0.89 | RIPK2 (0.53) | PTGER4RIPK2KDM4EHPGDMAPT | |
| SCHEMBL14616823 | 0.89 | RIPK2 (0.47) | PTGER4RIPK2KDM4EALDH1A1POLB | |
| SCHEMBL14616796 | 0.88 | RIPK2 (0.53) | PTGER4RIPK2KDM4EHPGDALDH1A1 | |
| SCHEMBL14616822 | 0.87 | RIPK2 (0.46) | PTGER4RIPK2 | |
| SCHEMBL14616821 | 0.87 | RIPK2 (0.46) | PTGER4RIPK2HPGDMAPTNPSR1 | |
| SCHEMBL14616799 | 0.86 | RIPK2 (0.51) | PTGER4RIPK2KDM4EHPGDALDH1A1 | |
| SCHEMBL14576006 | 0.86 | PTGER4 (0.50) | PTGER4RIPK2CA12CA9CA1 | |
| SCHEMBL14616801 | 0.85 | RIPK2 (0.49) | PTGER4RIPK2KDM4EHPGDNPSR1 | |
| SCHEMBL14642983 | 0.85 | RIPK2 (0.60) | PTGER4RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | PTGER4 3190/4885RIPK2 255/4885CA12 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.